The Discussion of Regulatory Inspection Key Points Based on the ProductionTechnology of Immune Cell Therapy Products

Dong Xuejiao, Guo Linfeng, Zheng Tianlei, Zhang Laijun

Chinese Pharmaceutical Affairs ›› 2024, Vol. 38 ›› Issue (3) : 245-249.

Chinese Pharmaceutical Affairs ›› 2024, Vol. 38 ›› Issue (3) : 245-249. DOI: 10.16153/j.1002-7777.2024.03.001
Supervision Administration

The Discussion of Regulatory Inspection Key Points Based on the ProductionTechnology of Immune Cell Therapy Products

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 38(3): 245-249 https://doi.org/10.16153/j.1002-7777.2024.03.001

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉